Login to Your Account



Deals And M&A NEWS

The acquisition of two partner-ready nanoparticle cancer candidates developed by Azaya Therapeutics Inc. and an associated nanotech platform could yield potential near-term revenue for Cytori Therapeutics Inc.

Eli Lilly and Co.'s takeover of Colucid Pharmaceuticals Inc. for about $960 million calmed some investor frets brought on by patent rulings in the EU and led to speculation about further deals among migraine players.

Takeda Pharmaceutical Co. Ltd. and Ovid Therapeutics Inc. have agreed to jointly develop and commercialize Takeda's TAK-935 in rare pediatric epilepsies, splitting costs and potential profits 50-50.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: